Literature DB >> 8219114

Interleukin-2 prevents programmed cell death in chronic lymphocytic leukemia cells.

R W Huang1, H Tsuda, K Takatsuki.   

Abstract

When B-cell chronic lymphocytic leukemia (B-CLL) cells derived from peripheral blood are cultured in vitro, a substantial proportion die spontaneously by programmed cell death (PCD). In this study, we reexamined this phenomenon with both B-CLL and T-CLL cells, using a serum-free culture system. After 48 h of culture, in B-CLL cells, 23.3% +/- 6.7% (mean +/- S.E.M., n = 3) of total DNA was fragmented, while in 2 cases of T-CLL, this value was 32% and 45%, respectively. Analysis by electrophoresis indicated that the DNA of the B-CLL and T-CLL cells had been cleaved into regular oligonucleosome fragments comprising approximately 180-200 base pairs. This process was significantly promoted by methylprednisolone and the protein kinase A (PKA) activator Sp-cAMPS in at least some cases. Since B-CLL and T-CLL cells often possess interleukin-2 (IL-2) receptors on their cell membranes, we assessed the effects of IL-2 on spontaneous PCD. After a 48-h culture PCD was inhibited by 100 units/ml IL-2 by 31.7% +/- 6.6% in B-CLL (n = 3) and by 47% in one of 2 cases of T-CLL. This protective effect of IL-2 against spontaneous PCD was dose- and time-dependent. These findings suggest that the viability of B-CLL and T-CLL cells in vivo is regulated both positively and negatively by intrinsic IL-2, glucocorticoids, and regulators of PKA activity. This process of cell death may be involved in the development of CLL.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8219114

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  4 in total

Review 1.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

2.  Cytokine expression in B-CLL in relation to disease progression and in vitro activation.

Authors:  M Aguilar-Santelises; D Gigliotti; L M Osorio; A D Santiago; H Mellstedt; M Jondal
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

3.  Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.

Authors:  T Robak; A Wierzbowska; M Błasińska-Morawiec; A Korycka; J Z Błoński
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

4.  A case of comorbid myxoma and chronic lymphocytic leukemia: not just a coincidence?

Authors:  Heather Laird-Fick; Ashish Tiwari; Santhosshi Narayanan; Ying Qin; Deepthi Vodnala; Manisha Bhutani
Journal:  Case Rep Oncol Med       Date:  2014-04-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.